343 related articles for article (PubMed ID: 16777780)
1. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
4. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
5. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
6. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
7. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
8. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
9. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment.
Toral-Martiñón R; Shkurovich-Bialik P; Collado-Corona MA; Mora-Magaña I; Goldgrub-Listopad S; Shkurovich-Zaslavsky M
Arch Med Res; 2003; 34(3):205-8. PubMed ID: 14567400
[TBL] [Abstract][Full Text] [Related]
10. An objective method of analyzing cochlear versus noncochlear patterns of distortion-product otoacoustic emissions in patients with acoustic neuromas.
Telischi F
Laryngoscope; 2000 Apr; 110(4):553-62. PubMed ID: 10763999
[TBL] [Abstract][Full Text] [Related]
11. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
12. The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions.
Riga M; Psarommatis I; Korres S; Lyra Ch; Papadeas E; Varvutsi M; Ferekidis E; Apostolopoulos N
Int J Pediatr Otorhinolaryngol; 2006 Jun; 70(6):1003-8. PubMed ID: 16359737
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
14. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
15. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
16. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
18. Distortion product otoacoustic emissions in an industrial setting.
Korres GS; Balatsouras DG; Tzagaroulakis A; Kandiloros D; Ferekidou E; Korres S
Noise Health; 2009; 11(43):103-10. PubMed ID: 19414930
[TBL] [Abstract][Full Text] [Related]
19. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
Delehaye E; Capobianco S; Bertetto IB; Meloni F
Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
[TBL] [Abstract][Full Text] [Related]
20. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]